Molnupiravir (Molnarz™) is the only Molnupiravir that was granted Emergency Use Authorization (EUA) by the Philippine Food and Drug Administration to Faberco Life Sciences Inc., (FLSI).
Molnarz™ is manufactured by Aurobindo Pharma Ltd., the top branded generic drug manufacturer in India under license by Merck, USA. The dosage is 800 mg (4 capsules of 200 mg); 2 times a day for 5 days prescribed and given to confirmed mild and moderate cases of COVID-19. It should be given within the first 5 days following positive COVID-19 result confirmation.
Several local government units (LGUs), hospitals and other health facilities have been served with Molnupiravir (Molnarz™).
Faberco Life Sciences is committed to address the urgent need for Molnupiravir and ensure to allocate enough supply to respond the surging need in the coming days. For inquiries on how to access Molnupiravir, the medical community is advised to direct their concerns to the following:
1) Faberco Life Sciences website: https://faberco.ph
2) Dr. Ma. Luningning Elio Villa, Medical Director, FLSI, Mobile: +63 9958765550, Email: firstname.lastname@example.org
3) Ms. Sherry Panemanglor, Business Development Head, FLSI, Mobile: +63 917 541 1118, Email: email@example.com
ABOUT FABERCO LIFE SCIENCES, INC.
Faberco Life Sciences Inc. is a Philippine Biopharmaceutical focused on providing innovative, safe and effective products that will help address life threatening diseases of public health concern. Together with reputable international manufacturers as our partners, we will be able to respond to the healthcare needs of the Filipino people in improving lives.
Nothing’s sweeter than being able to reap the rewards of your hard work. All those hours you’ve put in and...Read more